Rapid communication Open Access
Like 0


We use surveillance data to describe influenza A and B virus circulation over two consecutive seasons with excess all-cause mortality in Europe, especially in people aged 60 years and older. Influenza A(H3N2) virus dominated in 2016/17 and B/Yamagata in 2017/18. The latter season was prolonged with positivity rates above 50% among sentinel detections for at least 12 weeks. With a current west–east geographical spread, high influenza activity might still be expected in eastern Europe.


Article metrics loading...

Loading full text...

Full text loading...



  1. European monitoring of excess mortality for public health action - EuroMOMO. Copenhagen: EuroMOMO. [Accessed 23 Mar 2018]. Available from: http://www.euromomo.eu/index.html
  2. Vestergaard LS, Nielsen J, Krause TG, Espenhain L, Tersago K, Bustos Sierra N, et al. Excess all-cause and influenza-attributable mortality in Europe, December 2016 to February 2017. Euro Surveill. 2017;22(14):30506.  https://doi.org/10.2807/1560-7917.ES.2017.22.14.30506  PMID: 28424146 
  3. European Centre for Disease Prevention and Control (ECDC) and World Health Organization (WHO) Regional Office for Europe. Flu News Europe - Joint ECDC-WHO/Europe weekly influenza update, Archives season 2017-18. Week 11/2018 (12–18 March 2018). ECDC/WHO. Available from: http://flunewseurope.org/Archives
  4. Paget J, Marquet R, Meijer A, van der Velden K. Influenza activity in Europe during eight seasons (1999-2007): an evaluation of the indicators used to measure activity and an assessment of the timing, length and course of peak activity (spread) across Europe. BMC Infect Dis. 2007;7(1):141.  https://doi.org/10.1186/1471-2334-7-141  PMID: 18047685 
  5. Meijer A, Valette M, Manuguerra JC, Pérez-Breña P, Paget J, Brown C, et al. Implementation of the community network of reference laboratories for human influenza in Europe. J Clin Virol. 2005;34(2):87-96.  https://doi.org/10.1016/j.jcv.2005.02.005  PMID: 16157259 
  6. Meijer A, Brown C, Hungnes O, Schweiger B, Valette M, van der Werf S, et al. Programme of the Community Network of Reference Laboratories for Human Influenza to improve Influenza Surveillance in Europe. Vaccine. 2006;24(44-46):6717-23.  https://doi.org/10.1016/j.vaccine.2006.05.068  PMID: 16782242 
  7. European Centre for Disease prevention and Control (ECDC). Risk assessment update: seasonal influenza, EU/EEA, 2016-2017. Stockholm: ECDC; 25 Jan 2017. Available from: https://ecdc.europa.eu/en/publications-data/risk-assessment-update-seasonal-influenza-eueea-2016-2017
  8. Budd AP, Wentworth DE, Blanton L, Elal AIA, Alabi N, Barnes J, et al. Update: Influenza Activity - United States, October 1, 2017-February 3, 2018. MMWR Morb Mortal Wkly Rep. 2018;67(6):169-79.  https://doi.org/10.15585/mmwr.mm6706a1  PMID: 29447145 
  9. Adlhoch C, Broberg E, Beauté J, Snacken R, Bancroft E, Zucs P, et al. Influenza season 2013/14 has started in Europe with influenza A(H1)pdm09 virus being the most prevalent subtype. Euro Surveill. 2014;19(4):20686.  https://doi.org/10.2807/1560-7917.ES2014.19.4.20686  PMID: 24507465 
  10. European monitoring of excess mortality for public health action - EuroMoMo. Pooled analyses of all-cause mortality indicates low excess mortality in Europe in the winter of 2013/14, in particular amongst the elderly. 2014. Copenhagen: EuroMOMO. [Accessed 23 Mar 2018]. Available from: http://www.euromomo.eu/methods/pdf/pooled_analyses_winter_2013_14.pdf
  11. Beauté J, Broberg E, Plata F, Bonmarin I, O Donnell J, Delgado C, et al. Overrepresentation of influenza A(H1N1)pdm09 virus among severe influenza cases in the 2011/12 season in four European countries. Euro Surveill. 2012;17(9):20105. PMID: 22401564 
  12. Pebody R, Warburton F, Ellis J, Andrews N, Potts A, Cottrell S, et al. End-of-season influenza vaccine effectiveness in adults and children, United Kingdom, 2016/17. Euro Surveill. 2017;22(44):17-00306.  https://doi.org/10.2807/1560-7917.ES.2017.22.44.17-00306  PMID: 29113630 
  13. Tran D, Vaudry W, Moore D, Bettinger JA, Halperin SA, Scheifele DW, et al. Hospitalization for Influenza A Versus B. Pediatrics. 2016;138(3):e20154643.  https://doi.org/10.1542/peds.2015-4643  PMID: 27535144 
  14. Snacken R, Quinten C, Devaux I, Plata F, Broberg E, Zucs P, et al. Surveillance of hospitalised severe cases of influenza A(H1N1)pdm09 and related fatalities in nine EU countries in 2010-2011. Influenza Other Respi Viruses. 2012;6(6):e93-6.  https://doi.org/10.1111/j.1750-2659.2012.00406.x  PMID: 22788875 
  15. Karageorgopoulos DE, Vouloumanou EK, Korbila IP, Kapaskelis A, Falagas ME. Age distribution of cases of 2009 (H1N1) pandemic influenza in comparison with seasonal influenza. PLoS One. 2011;6(7):e21690.  https://doi.org/10.1371/journal.pone.0021690  PMID: 21747947 
  16. World Health Organization (WHO) Regional Office for Europe. Influenza surveillance country profiles of WHO European Region Member States 2017. Copenhagen: WHO. [Accessed 12 Feb 2018]. Available from: http://www.euro.who.int/en/health-topics/communicable-diseases/influenza/surveillance-and-lab-network/influenza-surveillance-country-profiles/influenza-surveillance-country-profiles-of-who-european-region-member-states
  17. Rondy M, Kissling E, Emborg H-D, Gherasim A, Pebody R, Trebbien R, et al. Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies. Euro Surveill. 2018;23(9):18-00086.  https://doi.org/10.2807/1560-7917.ES.2018.23.9.18-00086  PMID: 29510782 
  18. European Centre for Disease Prevention and Control (ECDC). Seasonal influenza vaccination in Europe; Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons, 2007–2008 to 2014–2015. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/en/publications-data/seasonal-influenza-vaccination-europe-vaccination-recommendations-and-coverage-2007-2015
  19. European Centre for Disease Prevention and Control (ECDC). Expert Opinion on neuraminidase inhibitors for prevention and treatment of influenza – review of recent systematic reviews and meta-analyses. Stockholm: ECDC; 2017. Available from: https://ecdc.europa.eu/sites/portal/files/documents/Scientific-advice-neuraminidase-inhibitors-2017.pdf

Data & Media loading...

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error